These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20583882)

  • 1. Development and performance of the zotarolimus-eluting Endeavor coronary stent.
    Kandzari DE
    Expert Rev Med Devices; 2010 Jul; 7(4):449-59. PubMed ID: 20583882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
    Kandzari DE; Leon MB
    J Interv Cardiol; 2006 Oct; 19(5):405-13. PubMed ID: 17020565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients.
    Gershlick A; Kandzari DE; Leon MB; Wijns W; Meredith IT; Fajadet J; Popma JJ; Fitzgerald PJ; Kuntz RE;
    Am J Cardiol; 2007 Oct; 100(8B):45M-55M. PubMed ID: 17950832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
    Camenzind E; Wijns W; Mauri L; Boersma E; Parikh K; Kurowski V; Gao R; Bode C; Greenwood JP; Gershlick A; O'Neill W; Serruys PW; Jorissen B; Steg PG;
    Am Heart J; 2009 Dec; 158(6):902-909.e5. PubMed ID: 19958855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent.
    Zhang F; Qian J; Ge J
    J Invasive Cardiol; 2008 Aug; 20(8):423-5. PubMed ID: 18688068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of drug-eluting stents.
    Windecker S; Jüni P
    Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):316-28. PubMed ID: 18414453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III.
    Mehta RH; Leon MB; Sketch MH;
    Am J Cardiol; 2007 Oct; 100(8B):62M-70M. PubMed ID: 17950834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
    Suttorp MJ; Laarman GJ;
    Am Heart J; 2007 Sep; 154(3):432-5. PubMed ID: 17719285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
    Kandzari DE; Leon MB; Popma JJ; Fitzgerald PJ; O'Shaughnessy C; Ball MW; Turco M; Applegate RJ; Gurbel PA; Midei MG; Badre SS; Mauri L; Thompson KP; LeNarz LA; Kuntz RE;
    J Am Coll Cardiol; 2006 Dec; 48(12):2440-7. PubMed ID: 17174180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.
    Rodriguez AE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):561-76. PubMed ID: 19712016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.